CKD-828 (80/5mg) Pharmacokinetic Study
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-828
Telmisartan
S-amlodipine
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, CKD-828, Telmisartan, S-amlodipine, Pharmacokinetic
Eligibility Criteria
Inclusion Criteria:
- A healthy volunteer between 20 and 55 years old
- More than 50kg and within 20% of ideal body weight
- No any congenital or chronic diseases and medical symptom
- Appropriate for the study from examination(laboratory test, ECG etc.) within 4weeks prior to the first IP administration
- Signed the informed consent form prior to the study participation.
Exclusion Criteria:
- History of relevant hypersensitivity against drug
- Clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, CNS etc.)
- Active liver disease or abnormal laboratory result (AST or ALT or Total bilirubin > 1.5*ULN)
- SBP <90mmHg or SBP >150mmHg
- DBP <50mmHg or DBP >100mmHg
- Creatinine clearance <80mL/min
- A Disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastro-intestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug
- The evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first IP administration.
- A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day)
- Taking ETC medicine or oriental medicine within 14days or Taking OTC medicine within 7days prior to the first IP administration
- Abnormal diet(Especially, grapefruit juice within 7 days prior to the first IP administration) that may influence on the absorption, distribution, metabolism and excretion of the drug
Sites / Locations
- Kyungpook National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
CKD-828(Fixed Dose Combination)
Combination Therapy
Arm Description
FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
Coadministration of Telmisartan 80mg and S-amlodipine 5mg
Outcomes
Primary Outcome Measures
Cmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
AUClast after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Secondary Outcome Measures
Tmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
t1/2 after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
AUCinf after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Number of participants with adverse events
Adverse Event monitoring
Evaluated safety parameters included: Physical examination, Vital sign, ECG, laboratory test
Full Information
NCT ID
NCT02250833
First Posted
September 22, 2014
Last Updated
April 8, 2015
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT02250833
Brief Title
CKD-828 (80/5mg) Pharmacokinetic Study
Official Title
To Compare the Pharmacokinetics and Safety of CKD-828 80/5mg to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
A randomized, open-label, single-dose, two-period, two-way, crossover study to compare the pharmacokinetics and safety CKD-828 (Fixed Dose Combination Tablet) to coadministration telmisartan and s-amlodipine in health volunteers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, CKD-828, Telmisartan, S-amlodipine, Pharmacokinetic
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
69 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CKD-828(Fixed Dose Combination)
Arm Type
Experimental
Arm Description
FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
Arm Title
Combination Therapy
Arm Type
Active Comparator
Arm Description
Coadministration of Telmisartan 80mg and S-amlodipine 5mg
Intervention Type
Drug
Intervention Name(s)
CKD-828
Other Intervention Name(s)
Telminuvo
Intervention Description
Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
Intervention Type
Drug
Intervention Name(s)
Telmisartan
Other Intervention Name(s)
Micardis
Intervention Description
- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
Intervention Type
Drug
Intervention Name(s)
S-amlodipine
Other Intervention Name(s)
Anydipine s
Intervention Description
- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
Primary Outcome Measure Information:
Title
Cmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
AUClast after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Secondary Outcome Measure Information:
Title
Tmax after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
t1/2 after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
AUCinf after administration of CKD-828(Fixed Dose Combination) tablet and coadministration of corresponding dose of telmisartan and s-amlodipine.
Time Frame
up to 168 hours post dose
Title
Number of participants with adverse events
Description
Adverse Event monitoring
Evaluated safety parameters included: Physical examination, Vital sign, ECG, laboratory test
Time Frame
up to 31days post dose
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
A healthy volunteer between 20 and 55 years old
More than 50kg and within 20% of ideal body weight
No any congenital or chronic diseases and medical symptom
Appropriate for the study from examination(laboratory test, ECG etc.) within 4weeks prior to the first IP administration
Signed the informed consent form prior to the study participation.
Exclusion Criteria:
History of relevant hypersensitivity against drug
Clinical significant disease or medical history (ex. hepato/cholangio, cardio, endo, hemato, onco, CNS etc.)
Active liver disease or abnormal laboratory result (AST or ALT or Total bilirubin > 1.5*ULN)
SBP <90mmHg or SBP >150mmHg
DBP <50mmHg or DBP >100mmHg
Creatinine clearance <80mL/min
A Disease(ex.inflammatory intestinal disease, gastric or duodenal ulcer ,hepatic disease history , gastro-intestinal surgery except for appendectomy)that may influence on the absorption, distribution, metabolism and excretion of the drug
The evidence of severe attack or acute disease or surgical intervention within 28 days prior to the first IP administration.
A drug abuse or a heavy caffeine consumer (more than 5 cups per a day) or regular alcohol consumer(more than 21 units/week) or a heavy smoker(more than 10 cigarettes per a day)
Taking ETC medicine or oriental medicine within 14days or Taking OTC medicine within 7days prior to the first IP administration
Abnormal diet(Especially, grapefruit juice within 7 days prior to the first IP administration) that may influence on the absorption, distribution, metabolism and excretion of the drug
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Young-Ran Yoon
Organizational Affiliation
Kyungpook National University Hospital Clinical Trial Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kyungpook National University Hospital
City
Daegu, samdeok-dong, 2-ga 50
State/Province
samdeok-dong, 2-ga 50 Jung-gu
ZIP/Postal Code
700-721
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
CKD-828 (80/5mg) Pharmacokinetic Study
We'll reach out to this number within 24 hrs